Free Newsletter
Drug-suicide link complex, data elusive
Is it possible to draw a straight line between patient suicide and prescription drugs? It's a touchy subject. Within the last few weeks, the FDA alerted the public that epilepsy drugs appear to boost the remote risk of suicide (or at least suicidal thoughts), that Pfizer's stop-smoking drug Chantix may do the same, and that it's requiring more suicide-related data in drug trials. Is suicide the scary drug risk du jour? Or is the explosion activity long overdue?
The New York Times examines the question today and basically concludes that clarity will be elusive. Unless, that is, lawmakers mandate massive databases of patient-and-drug info designed to sift out rare side effects.
- check out the NYT's release
Related Articles:
FDA: Chantix may pose psych risks. Report
FDA gets 5,000 Chantix complaints. Report
'Erratic' behavior triggers Chantix probe. Report
FDA: Epilepsy drugs boost suicidal thoughts. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: